Clinical Trial Update: Copeptin for Risk Stratification in Acute Stroke Patients: the CoRisk Study

View source ↗

Summary

The CoRisk clinical trial evaluating copeptin as a biomarker for risk stratification in patients with acute stroke and transient ischemic attack has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Stroke, Transient Ischemic Attack | Status: COMPLETED